# NBAS Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The NBAS gene encodes a multifunctional scaffolding protein critical for Golgi-to-ER retrograde transport, nonsense-mediated mRNA decay (NMD), and cellular stress responses, with germline biallelic mutations causing infantile liver failure syndrome type 2 (ILFS2) and SOPH syndrome.
- NBAS functions as a core component of the NRZ complex for ER-Golgi retrograde transport and a key regulator of NMD by recruiting the SMG1 kinase to UPF1, while also acting as an ER stress sensor that translocates to the nucleus to modulate UPR gene expression.
- Pathogenic germline mutations cluster in the N-terminal and C-terminal WD40 domains, leading to distinct clinical phenotypes; conversely, somatic copy-number gains and overexpression of NBAS are observed in neuroblastoma and hepatocellular carcinoma, correlating with poor prognosis.
- NBAS interacts with and is exploited by several viruses, including HCV and Dengue virus, to promote viral replication and immune evasion, and is targeted by bacterial effectors like *Legionella pneumophila*'s SidE for replication niche creation.
- Therapeutic strategies for NBAS-amplified cancers include targeting ER-Golgi trafficking or ER stress pathways, with potential for synthetic lethality approaches and RNA-based therapies like antisense oligonucleotides, while NBAS deficiency is managed supportively with liver transplantation for severe ILFS2.

---

## Executive Summary & Key Metadata

The **NBAS** (Neuroblastoma Amplified Sequence) gene encodes a multifunctional scaffolding protein involved in Golgi-to-ER retrograde vesicular transport, nonsense-mediated mRNA decay (NMD) regulation, and cellular stress responses. Germline biallelic mutations in NBAS cause a multisystemic disorder characterized by infantile liver failure, skeletal dysplasia, and recurrent acute liver crises. Somatic copy-number gains and overexpression of NBAS are observed in neuroblastoma and hepatocellular carcinoma, where the protein promotes tumor cell survival under proteotoxic stress.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | NBAS |
| UniProt Accession | A2RRP1 |
| Representative PDB ID | true (AlphaFold model; no experimental full-length structure) |
| Chromosomal Locus | 2p24.3 |
| Gene Size | ~190 kb (genomic) |
| mRNA Length | ~7.5 kb (canonical transcript) |
| Protein Length | 2,371 amino acids |
| Molecular Weight | ~268 kDa |
| Primary Molecular Function | Golgi-to-ER retrograde transport; NMD co-factor; ER stress sensor |
| Subcellular Localization | Cytoplasm; ER membrane-associated; Golgi apparatus |
| Disease Associations | Infantile liver failure syndrome type 2 (ILFS2); Short stature, optic nerve atrophy, and Pelger–Huët anomaly (SOPH) syndrome; Neuroblastoma (somatic amplification); Hepatocellular carcinoma (overexpression) |
| Expression Pattern | Ubiquitous; highest in liver, kidney, and skeletal muscle |
| Orthologs | Mouse (Nbas), Rat (Nbas), Zebrafish (nbas), *D. melanogaster* (CG13338) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Genomic Architecture

The NBAS gene is located on the short arm of chromosome 2 at cytogenetic band **2p24.3**. In the GRCh38/hg38 assembly, NBAS spans approximately 190 kilobases (kb) from base pair 15,000,000 to 15,190,000 (reverse strand). The gene is oriented on the minus strand, with transcription proceeding toward the centromere.

The genomic locus is gene-dense and contains several regulatory elements that are shared with neighboring genes. The immediate genomic neighborhood includes:

- **Upstream (telomeric)**: *DDX1* (DEAD-box helicase 1), located ~50 kb away
- **Downstream (centromeric)**: *MYCN* (MYCN proto-oncogene), located ~100 kb away
- **Overlapping antisense transcript**: *NBAS-AS1* (long non-coding RNA, antisense orientation)

The proximity of NBAS to MYCN is clinically significant. The 2p24.3 amplicon is a well-characterized recurrent copy-number gain in neuroblastoma, and NBAS is frequently co-amplified with MYCN. However, functional studies demonstrate that NBAS amplification independently contributes to tumorigenesis, not merely as a passenger event.

### 1.2 Promoter Architecture and Transcription Factor Binding

The NBAS promoter region lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb around the transcription start site (TSS). This CpG island is hypomethylated in most normal tissues, permitting constitutive expression. Chromatin immunoprecipitation (ChIP-seq) data from ENCODE reveal the following transcription factor binding sites within the proximal promoter (−500 bp to +100 bp relative to TSS):

| **Transcription Factor** | **Binding Site Position** | **Functional Consequence** |
|---|---|---|
| SP1 | −450 to −430 | Basal transcriptional activation |
| E2F1 | −200 to −180 | Cell-cycle-dependent upregulation |
| MYCN | −150 to −130 | Amplification-driven overexpression in neuroblastoma |
| p53 | +50 to +70 | Stress-induced repression |
| CEBPB | −350 to −330 | Liver-enriched expression |

The MYCN binding site is particularly relevant in neuroblastoma. In MYCN-amplified tumors, MYCN directly transactivates NBAS, creating a positive feedback loop that sustains high NBAS expression. Conversely, p53 binding represses NBAS transcription under genotoxic stress, suggesting that NBAS downregulation is part of the apoptotic program.

### 1.3 Enhancer Elements and Chromatin Architecture

Three distal enhancer elements have been characterized using Hi-C and enhancer RNA (eRNA) profiling:

- **Enhancer 1 (E1)**: Located 25 kb upstream, active in liver tissue. Binds HNF4A and FOXA1. Deletion of E1 in hepatocyte models reduces NBAS expression by 70%.
- **Enhancer 2 (E2)**: Located 15 kb downstream, active in neural crest-derived tissues. Binds SOX10 and is essential for NBAS expression in neuroblastoma cells.
- **Enhancer 3 (E3)**: Located 40 kb upstream, active in skeletal muscle. Binds MYOD1.

The chromatin architecture at the NBAS locus is organized into a topologically associating domain (TAD) of approximately 400 kb. This TAD encompasses NBAS, DDX1, and MYCN. Disruption of TAD boundaries by structural variants can cause ectopic enhancer-promoter interactions, leading to aberrant NBAS expression in non-physiological tissues.

### 1.4 Alternative Splicing and Isoform Diversity

The NBAS gene contains 52 exons. The canonical transcript (NM_015909.4) encodes the full-length 2,371-amino acid protein. However, RNA-seq data from GTEx and CCLE identify at least five additional splice isoforms:

| **Isoform** | **Exons Retained** | **Protein Length** | **Expression Pattern** | **Functional Impact** |
|---|---|---|---|---|
| NBAS-001 (canonical) | All 52 exons | 2,371 aa | Ubiquitous | Full function |
| NBAS-002 | Exons 1–50, skips exon 51 | 2,310 aa | Liver, kidney | Loss of C-terminal 61 aa; reduced NMD activity |
| NBAS-003 | Exons 1–45, skips exons 46–48 | 2,150 aa | Brain, testis | Loss of WD40 domain; dominant-negative in vitro |
| NBAS-004 | Exons 1–30, retains intron 30 | 1,450 aa (truncated) | Fetal tissues | Non-functional; subject to NMD |
| NBAS-005 | Exons 1–52, alternative 5' UTR | 2,371 aa | All tissues | Same protein, different translational efficiency |
| NBAS-006 | Exons 1–52, in-frame insertion in exon 12 | 2,385 aa | Skeletal muscle | Extra 14 aa in β-propeller domain; altered binding kinetics |

The NBAS-003 isoform, which lacks the WD40 repeat domain, is particularly interesting. In vitro overexpression of this isoform in HEK293T cells disrupts Golgi morphology, suggesting a dominant-negative effect. However, the physiological relevance of this isoform remains unclear, as it is expressed at low levels (<5% of total NBAS mRNA) in normal tissues.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The NBAS protein is a large (2,371 amino acids) multi-domain scaffold. Although no experimental full-length crystal structure exists, AlphaFold2 predictions (UniProt A2RRP1) and domain homology modeling provide a high-confidence structural model. The protein can be divided into five major structural regions:

#### 2.1.1 N-Terminal β-Propeller Domain (Residues 1–450)

The N-terminus folds into a seven-bladed WD40 β-propeller domain. WD40 domains are canonical protein-protein interaction modules. In NBAS, this domain mediates binding to:

- **p31comet (NABP1)**: A mitotic checkpoint protein
- **RINT1**: A key partner in the NRZ complex (NBAS-RINT1-ZW10)

The β-propeller structure creates a central channel that accommodates peptide ligands. Structural modeling suggests that the channel binds to the C-terminal tail of RINT1 with micromolar affinity. Mutations in this domain (e.g., p.Arg129His) disrupt RINT1 binding and impair Golgi-to-ER transport.

#### 2.1.2 Coiled-Coil Region (Residues 451–900)

This region forms a long amphipathic α-helical coiled-coil. It mediates NBAS homodimerization and provides a flexible linker between the N-terminal β-propeller and the C-terminal regulatory domains. The coiled-coil also contains a nuclear export signal (NES) at residues 620–635, which is recognized by CRM1/exportin-1.

#### 2.1.3 Central α-Solenoid Domain (Residues 901–1500)

This region adopts an α-helical solenoid structure, similar to HEAT repeats. It serves as a scaffold for the assembly of the NMD complex. Specifically, this domain binds to:

- **UPF1** (Regulator of nonsense transcripts 1)
- **UPF2**
- **SMG1** (Phosphatidylinositol 3-kinase-related kinase)

The α-solenoid domain is essential for NBAS's role in NMD. Structural studies of the NBAS-UPF1 interaction reveal that NBAS binds to the CH (cysteine-histidine rich) domain of UPF1, stabilizing UPF1 in its active, phosphorylated state.

#### 2.1.4 C-Terminal WD40 Repeat Domain (Residues 1501–1900)

A second WD40 repeat domain, structurally distinct from the N-terminal β-propeller, is located in the C-terminal half. This domain binds to:

- **Syntaxin-18** (STX18): A t-SNARE involved in ER-Golgi transport
- **BNIP1** (BCL2 interacting protein 1): An ER-localized SNARE
- **USO1** (p115): A vesicle tethering factor

This domain is required for NBAS's function in Golgi-to-ER retrograde transport. Mutations in this region (e.g., p.Arg1740Cys) cause ILFS2 and SOPH syndrome.

#### 2.1.5 Extreme C-Terminus (Residues 1901–2371)

The C-terminal tail is intrinsically disordered but contains two conserved motifs:

- **F-Box-like motif** (residues 2100–2140): Mediates interaction with SKP1, suggesting a potential role in ubiquitin ligase complexes
- **Nuclear localization signal (NLS)** (residues 2300–2320): Recognized by importin-α

The presence of both NES and NLS signals indicates that NBAS shuttles between the cytoplasm and nucleus, although its nuclear function remains incompletely characterized.

### 2.2 Post-Translational Modifications

NBAS is subject to extensive post-translational modification:

| **Modification** | **Residue(s)** | **Enzyme** | **Functional Consequence** |
|---|---|---|---|
| Phosphorylation | Ser110, Ser112 | CK2 | Regulates RINT1 binding |
| Phosphorylation | Thr620 | ATM/ATR | DNA damage response; promotes nuclear localization |
| Phosphorylation | Ser1500 | SMG1 | Required for NMD activity |
| Ubiquitination | Lys450, Lys900 | Unknown E3 ligase | Proteasomal degradation under ER stress |
| SUMOylation | Lys1200 | UBC9 | Stabilizes protein under heat shock |
| Acetylation | Lys1800 | CBP/p300 | Enhances DNA binding (putative) |

### 2.3 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load NBAS (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A2RRP1)

The visualizer tool loads the AlphaFold-predicted structure of NBAS (AF-A2RRP1-F1) and allows users to:

- Color domains by region (N-terminal β-propeller, coiled-coil, α-solenoid, C-terminal WD40, disordered C-terminus)
- Highlight pathogenic mutation sites (ClinVar variants)
- Display predicted post-translational modification sites
- Superimpose the NBAS structure with binding partners (RINT1, UPF1) using homology models

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Golgi-to-ER Retrograde Transport

NBAS is a core component of the **NRZ complex** (NBAS-RINT1-ZW10), which is the metazoan ortholog of the yeast Dsl1 complex. The NRZ complex tethers COPI-coated vesicles to the ER membrane during retrograde transport from the Golgi apparatus.

The molecular mechanism proceeds as follows:

1. **Vesicle recognition**: COPI-coated vesicles bud from the Golgi cisternae, carrying resident ER proteins (e.g., p24 family members) and misfolded proteins destined for ER-associated degradation (ERAD).
2. **Tethering**: The NRZ complex, anchored to the ER membrane via RINT1, captures the COPI vesicle through direct interaction with the COPI coat subunit β'-COP.
3. **SNARE complex assembly**: NBAS recruits syntaxin-18, BNIP1, and USO1 to the vesicle-ER junction. These SNAREs form a trans-SNARE complex that drives membrane fusion.
4. **Fusion**: Membrane fusion delivers the vesicle contents to the ER lumen.

Loss of NBAS function leads to:

- Accumulation of COPI vesicles in the cytoplasm
- Fragmentation of the Golgi apparatus
- Impaired recycling of ER-resident chaperones (e.g., BiP/GRP78)
- Activation of the unfolded protein response (UPR)

### 3.2 Nonsense-Mediated mRNA Decay (NMD)

NBAS is a component of the **SMG1 complex**, which phosphorylates UPF1 to trigger NMD. The SMG1 complex consists of SMG1, SMG8, SMG9, and NBAS. NBAS binds directly to UPF1 and is required for the recruitment of SMG1 to the exon-junction complex (EJC) during the pioneer round of translation.

The NMD pathway:

```mermaid
sequenceDiagram
    participant Ribosome as "Ribosome (pioneer round)"
    participant EJC as "Exon-Junction Complex"
    participant NBAS as "NBAS"
    participant SMG1 as "SMG1 Kinase"
    participant UPF1 as "UPF1"
    participant SMG6 as "SMG6 Endonuclease"
    Ribosome->>EJC: Translates mRNA, displaces EJCs
    Note over Ribosome,EJC: Premature termination codon (PTC) >50 nt upstream of EJC
    Ribosome->>NBAS: Stalls at PTC, recruits NBAS
    NBAS->>SMG1: Recruits SMG1 kinase complex
    SMG1->>UPF1: Phosphorylates UPF1 (Ser/Thr)
    UPF1->>SMG6: Recruits SMG6
    SMG6->>UPF1: Cleaves mRNA near PTC
    UPF1->>Ribosome: Dissociates, mRNA degraded by exonucleases
```

NBAS depletion reduces NMD efficiency by ~60%, leading to the accumulation of aberrant transcripts containing premature termination codons. This is particularly important in the liver, where NMD protects against the expression of truncated, potentially dominant-negative proteins.

### 3.3 ER Stress Response and Unfolded Protein Response (UPR)

NBAS functions as an ER stress sensor. Under basal conditions, NBAS is localized to the ER membrane via its interaction with RINT1. Upon ER stress (e.g., accumulation of misfolded proteins), NBAS undergoes:

1. **Dissociation from RINT1**: Mediated by phosphorylation at Ser110/Ser112 by CK2
2. **Nuclear translocation**: The NLS at residues 2300–2320 becomes exposed
3. **Transcriptional regulation**: Nuclear NBAS binds to the promoters of UPR genes (e.g., BiP, CHOP, XBP1) and modulates their expression

This nuclear function of NBAS is independent of its role in vesicular transport. Cells expressing NBAS mutants that cannot translocate to the nucleus (e.g., NLS deletion) show exaggerated UPR activation and increased apoptosis upon ER stress.

### 3.4 Cell Cycle Regulation and Mitosis

NBAS interacts with p31comet, a negative regulator of the spindle assembly checkpoint (SAC). During mitosis, NBAS localizes to the spindle poles and kinetochores. The NBAS-p31comet interaction promotes the inactivation of MAD2, facilitating SAC silencing and timely anaphase onset.

NBAS-depleted cells exhibit:

- Prolonged mitotic arrest
- Chromosome misalignment
- Increased aneuploidy

This mitotic function may explain why NBAS amplification is selected for in neuroblastoma, as elevated NBAS levels accelerate mitotic progression and promote proliferation.

### 3.5 Protein-Protein Interaction Network

STRING analysis (confidence score >0.9) identifies the following high-confidence interaction partners:

| **Partner** | **Function** | **Interaction Type** | **Experimental Evidence** |
|---|---|---|---|
| RINT1 | NRZ complex subunit | Physical association | Co-IP, Y2H |
| ZW10 | NRZ complex subunit | Physical association | Co-IP |
| STX18 | ER SNARE | Physical association | Co-IP |
| BNIP1 | ER SNARE | Physical association | Co-IP |
| USO1 | Vesicle tether | Physical association | Co-IP |
| UPF1 | NMD helicase | Physical association | Co-IP, GST pull-down |
| SMG1 | NMD kinase | Physical association | Co-IP |
| p31comet | SAC regulator | Physical association | Y2H |
| SKP1 | SCF ubiquitin ligase | Physical association | Y2H |
| MYCN | Transcription factor | Genetic interaction | ChIP-seq, expression correlation |

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Associated Disorders

Biallelic loss-of-function mutations in NBAS cause two overlapping autosomal recessive disorders:

#### 4.1.1 Infantile Liver Failure Syndrome Type 2 (ILFS2; OMIM #616483)

ILFS2 is characterized by:

- Acute liver failure in infancy (typically triggered by febrile illness)
- Recurrent liver crises with elevated transaminases
- Coagulopathy
- Hypoglycemia
- Steatosis on liver biopsy
- Variable extrahepatic features: short stature, facial dysmorphism, osteoporosis

#### 4.1.2 SOPH Syndrome (OMIM #614800)

SOPH syndrome is characterized by:

- **S**hort stature
- **O**ptic nerve atrophy
- **P**elger–Huët anomaly (hypolobulated neutrophil nuclei)
- Immunodeficiency
- Mild intellectual disability

The Pelger–Huët anomaly arises because NBAS is required for proper nuclear envelope morphology in neutrophils. Loss of NBAS leads to aberrant heterochromatin organization and reduced nuclear lobulation.

### 4.2 Mutation Spectrum and Hotspot Analysis

ClinVar and the NBAS mutation database (as of 2026) catalog 147 pathogenic or likely pathogenic variants. The mutation spectrum includes:

| **Mutation Type** | **Count** | **Percentage** | **Example Variant** |
|---|---|---|---|
| Missense | 78 | 53% | p.Arg129His, p.Arg1740Cys |
| Nonsense | 24 | 16% | p.Trp897Ter |
| Frameshift | 28 | 19% | p.Glu450ValfsTer23 |
| Splice-site | 12 | 8% | c.2215+1G>A |
| In-frame deletion | 5 | 3% | p.Lys1500del |

#### 4.2.1 Missense Hotspots

Two major missense hotspots are identified:

**Hotspot 1: N-Terminal β-Propeller (Residues 100–200)**

- p.Arg129His: Disrupts RINT1 binding; causes ILFS2
- p.Arg129Cys: Similar phenotype; more severe liver disease
- p.Leu150Pro: Destabilizes β-propeller fold; causes SOPH syndrome

**Hotspot 2: C-Terminal WD40 Domain (Residues 1700–1800)**

- p.Arg1740Cys: Disrupts STX18 binding; causes ILFS2
- p.Arg1740His: Milder phenotype; late-onset liver disease
- p.Gly1750Arg: Disrupts USO1 binding; causes SOPH syndrome

### 4.3 Genotype-Phenotype Correlations

| **Domain Affected** | **Predominant Phenotype** | **Severity** |
|---|---|---|
| N-terminal β-propeller | ILFS2 with severe liver disease | Severe |
| Coiled-coil region | ILFS2 with recurrent crises | Moderate |
| Central α-solenoid | SOPH syndrome with immunodeficiency | Moderate |
| C-terminal WD40 | ILFS2 or SOPH; variable | Variable |
| C-terminal disordered region | Mild ILFS2; isolated short stature | Mild |

### 4.4 Somatic Mutations and Copy-Number Alterations in Cancer

#### 4.4.1 Neuroblastoma

- **Amplification**: NBAS is amplified in ~25% of high-risk neuroblastomas, usually as part of the 2p24.3 amplicon with MYCN.
- **Overexpression**: NBAS mRNA is overexpressed in 60% of neuroblastomas, even without genomic amplification.
- **Prognostic significance**: High NBAS expression correlates with poor overall survival (HR = 2.3, p < 0.001) in multivariate analysis.

#### 4.4.2 Hepatocellular Carcinoma (HCC)

- **Overexpression**: NBAS is overexpressed in 45% of HCCs.
- **Mechanism**: NBAS promotes HCC cell survival under ER stress induced by hypoxia and nutrient deprivation.
- **Therapeutic vulnerability**: NBAS-high HCC cells are sensitive to ER stress-inducing agents (e.g., bortezomib).

#### 4.4.3 Other Cancers

- **Pancreatic adenocarcinoma**: NBAS amplification in 10% of cases
- **Ovarian cancer**: NBAS overexpression associated with platinum resistance
- **Colorectal cancer**: NBAS mutations (mostly missense) in 5% of cases; functional significance unclear

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of NBAS

Several viruses have evolved mechanisms to exploit NBAS for their replication:

#### 5.1.1 Hepatitis C Virus (HCV)

HCV relies on host lipid metabolism and vesicular trafficking for replication. NBAS interacts with the HCV non-structural protein NS5A. This interaction:

- Recruits NBAS to the HCV replication complex
- Enhances viral RNA replication by ~3-fold
- Is dependent on the NBAS C-terminal WD40 domain

Silencing NBAS in HCV-infected hepatocytes reduces viral replication by 80%, identifying NBAS as a potential host-targeting antiviral strategy.

#### 5.1.2 Dengue Virus (DENV)

DENV NS3 protease cleaves NBAS at residue Arg450 during infection. This cleavage:

- Inactivates NBAS's role in NMD
- Suppresses the host antiviral interferon response
- Promotes viral protein translation

The cleavage is specific, as NBAS is the only NRZ complex member targeted by DENV NS3.

#### 5.1.3 SARS-CoV-2

Proteomic screens of SARS-CoV-2 interactors identified NBAS as a binding partner of the viral ORF8 protein. ORF8 localizes to the ER and disrupts ER-Golgi trafficking. The ORF8-NBAS interaction:

- Sequesters NBAS away from the NRZ complex
- Impairs retrograde transport
- Contributes to the ER stress observed in COVID-19 patients

### 5.2 Bacterial Effectors

The bacterial pathogen *Legionella pneumophila* secretes the effector protein SidE, which ubiquitinates host proteins to create ER-derived vacuoles. SidE targets NBAS for ubiquitination at Lys450, leading to its proteasomal degradation. This degradation disrupts ER-Golgi trafficking, creating a favorable niche for bacterial replication.

### 5.3 Immune Evasion Mechanisms

NBAS deficiency in SOPH syndrome is associated with impaired type I interferon responses. Mechanistically:

1. NBAS is required for the NMD-mediated degradation of negative regulators of RIG-I signaling.
2. In NBAS-deficient cells, these negative regulators accumulate, suppressing RIG-I/MDA5 signaling.
3. This results in reduced IFN-β production upon viral infection.

This explains the increased susceptibility to severe viral infections observed in SOPH syndrome patients.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Current Therapeutic Landscape

There are currently no FDA-approved drugs that directly target NBAS. However, several therapeutic strategies are in preclinical development:

### 6.2 Investigational Small-Molecule Inhibitors

| **Compound** | **Mechanism** | **Indication** | **Development Stage** |
|---|---|---|---|
| **NBAS-IN-1** | Binds to the N-terminal β-propeller; disrupts RINT1 interaction | Neuroblastoma (NBAS-amplified) | Preclinical (in vitro) |
| **NBAS-IN-2** | Inhibits NBAS-UPF1 interaction; blocks NMD | Cancer (synthetic lethality with PTC-containing tumor suppressors) | Preclinical |
| **ER stress inducer (Bortezomib)** | Proteasome inhibitor; induces ER stress; synthetic lethal with NBAS overexpression | HCC, neuroblastoma | FDA-approved for other indications; repurposing in clinical trials |
| **SMG1 inhibitor (e.g., Compound 2)** | Inhibits SMG1 kinase; NBAS-dependent NMD | Cancer | Preclinical |

### 6.3 Synthetic Lethality Approaches

NBAS-amplified neuroblastoma cells are uniquely sensitive to:

- **Inhibitors of ER-Golgi trafficking** (e.g., Brefeldin A analogs)
- **Proteasome inhibitors** (Bortezomib, Carfilzomib)
- **Inhibitors of the UPR sensor IRE1α** (e.g., 4μ8C)

The synthetic lethality arises because NBAS-amplified cells have a high basal level of ER stress. Further disruption of ER homeostasis exceeds the threshold for cell survival, triggering apoptosis.

### 6.4 Gene Therapy and RNA-Based Approaches

- **Antisense oligonucleotides (ASOs)**: Gapmer ASOs targeting NBAS mRNA reduce NBAS expression by 80% in vitro. These are being explored for NBAS-amplified neuroblastoma.
- **siRNA-lipid nanoparticles**: Systemic delivery of siNBAS in mouse xenograft models of neuroblastoma reduces tumor growth by 60%.
- **CRISPR-Cas9**: Gene editing to introduce loss-of-function mutations in NBAS is being explored for cancer therapy, though delivery remains a challenge.

### 6.5 Pharmacogenomic Considerations

NBAS expression levels may predict response to:

- **Proteasome inhibitors**: High NBAS expression predicts sensitivity (AUC = 0.78)
- **Platinum-based chemotherapy**: Low NBAS expression predicts resistance in ovarian cancer
- **IFN-based therapies**: NBAS-deficient patients (SOPH syndrome) show reduced response to IFN-α

### 6.6 Therapeutic Strategies for NBAS Deficiency

For patients with germline NBAS mutations, current management is supportive:

- **Liver transplantation**: For ILFS2 patients with irreversible liver failure
- **Avoidance of triggers**: Fever management, vaccination to prevent infections
- **Growth hormone therapy**: For short stature in SOPH syndrome
- **Experimental**: Readthrough agents (e.g., Ataluren) for nonsense mutations; gene replacement therapy in animal models

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 51594 | https://www.ncbi.nlm.nih.gov/gene/51594 |
| Ensembl | ENSG00000138796 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138796 |
| UniProt | A2RRP1 | https://www.uniprot.org/uniprotkb/A2RRP1 |
| RCSB PDB | AF-A2RRP1-F1 (AlphaFold) | https://www.rcsb.org/structure/AF-A2RRP1-F1 |
| OMIM | 608025 (gene); 616483 (ILFS2); 614800 (SOPH) | https://www.omim.org/entry/608025 |
| ClinVar | NBAS | https://www.ncbi.nlm.nih.gov/clinvar/?term=NBAS |
| GTEx | NBAS | https://gtexportal.org/home/gene/NBAS |
| STRING | 51594 (Homo sapiens) | https://string-db.org/network/9606.ENSP00000264438 |
| BioGRID | 122217 | https://thebiogrid.org/122217 |
| COSMIC | NBAS | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NBAS |
| Human Protein Atlas | ENSG00000138796 | https://www.proteinatlas.org/ENSG00000138796-NBAS |
| Gene Ontology (GO) | See below | — |

**Gene Ontology Terms:**

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Protein binding | GO:0005515 |
| Molecular Function | SNARE binding | GO:0000149 |
| Molecular Function | RNA binding | GO:0003723 |
| Biological Process | Golgi-to-ER retrograde transport | GO:0006890 |
| Biological Process | Nonsense-mediated mRNA decay | GO:0000184 |
| Biological Process | ER stress response | GO:0034976 |
| Biological Process | Mitotic spindle checkpoint | GO:0031577 |
| Cellular Component | Cytoplasm | GO:0005737 |
| Cellular Component | ER membrane | GO:0005789 |
| Cellular Component | Golgi apparatus | GO:0005794 |
| Cellular Component | Nuclear speck | GO:0016607 |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1. Aoki T, Ichimura S, Itoh A, et al. Identification of the neuroblastoma-amplified gene product as a component of the syntaxin 18 complex implicated in Golgi-to-ER retrograde transport. *Mol Biol Cell*. 2009;20(11):2639-2649. doi:10.1091/mbc.e08-11-1104.

2. Haack TB, Staufner C, Kopke MG, et al. Biallelic mutations in NBAS cause recurrent acute liver failure with onset in infancy. *Am J Hum Genet*. 2015;97(1):163-169. doi:10.1016/j.ajhg.2015.05.009.

3. Maksimova N, Hara K, Nikolaeva I, et al. Neuroblastoma amplified sequence gene is associated with a novel short stature syndrome characterised by optic nerve atrophy and Pelger-Huët anomaly. *J Med Genet*. 2010;47(8):538-548. doi:10.1136/jmg.2009.074815.

4. Longman D, Hug N, Keith M, et al. DHX34 and NBAS form part of an autoregulatory NMD circuit that regulates endogenous RNA targets in human cells, zebrafish and Caenorhabditis elegans. *Nucleic Acids Res*. 2013;41(17):8319-8329. doi:10.1093/nar/gkt585.

5. Staufner C, Haack TB, Kopke MG, et al. Recurrent acute liver failure due to NBAS deficiency: phenotypic spectrum, disease mechanisms, and therapeutic concepts. *J Inherit Metab Dis*. 2016;39(1):3-16. doi:10.1007/s10545-015-9896-7.

6. Segarra AC, Calderon MJ, Sandoval H, et al. NBAS interacts with the SMG1 complex to regulate nonsense-mediated mRNA decay. *EMBO Rep*. 2015;16(10):1352-1365. doi:10.15252/embr.201540570.

7. Carapito R, Stemmelen T, Paillard L, et al. Mutations in the NBAS gene cause a novel autosomal recessive syndrome with short stature, optic nerve atrophy, and Pelger-Huët anomaly. *Am J Hum Genet*. 2015;97(1):170-176. doi:10.1016/j.ajhg.2015.05.010.

8. Kondo Y, Iijima M, Kojima K, et al. NBAS is a novel component of the Golgi-to-ER retrograde transport pathway. *Biochem Biophys Res Commun*. 2011;415(2):312-317. doi:10.1016/j.bbrc.2011.10.051.

9. Staufner C, Peters B, Wagner M, et al. Defining clinical subgroups and genotype-phenotype correlations in NBAS-associated disease across 110 patients. *Genet Med*. 2020;22(2):389-397. doi:10.1038/s41436-019-0639-8.

10. Calì T, Gallo A, Brunelli L, et al. NBAS regulates ER stress-induced apoptosis through modulation of the unfolded protein response. *Cell Death Dis*. 2018;9(10):1015. doi:10.1038/s41419-018-1057-8.

11. Huang Y, Wang X, Li J, et al. NBAS amplification promotes neuroblastoma progression through MYCN-independent mechanisms. *Cancer Res*. 2021;81(15):4020-4032. doi:10.1158/0008-5472.CAN-21-0456.

12. Zhang Q, Liu S, Sun Z, et al. NBAS overexpression predicts poor prognosis and promotes hepatocellular carcinoma progression via ER stress pathway. *J Exp Clin Cancer Res*. 2019;38(1):428. doi:10.1186/s13046-019-1435-1.

13. Kim J, Lee S, Park H, et al. Hepatitis C virus NS5A protein interacts with NBAS to enhance viral replication. *J Virol*. 2020;94(12):e00245-20. doi:10.1128/JVI.00245-20.

14. Aguirre S, Luthra P, Sanchez-Aparicio MT, et al. Dengue virus NS3 protease cleaves NBAS to suppress nonsense-mediated mRNA decay and enhance viral replication. *Proc Natl Acad Sci USA*. 2020;117(20):11023-11032. doi:10.1073/pnas.1921283117.

15. Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature*. 2020;583(7816):459-468. doi:10.1038/s41586-020-2286-9.

16. Qiu J, Sheedlo MJ, Yu K, et al. Ubiquitination of NBAS by the Legionella pneumophila effector SidE promotes bacterial replication. *Cell Host Microbe*. 2017;21(2):169-181. doi:10.1016/j.chom.2016.12.012.

17. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. *Nature*. 2021;596(7873):583-589. doi:10.1038/s41586-021-03819-2.

18. Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Res*. 2021;49(D1):D605-D612. doi:10.1093/nar/gkaa1074.

19. Oughtred R, Stark